Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: Recent French data - The ANRS-Coquelicot study

Substance Use and Misuse

Volumn 41, Issue 10-12, 2006, Pages 1603-1621

  Jauffret Roustide, M ^a,b,e   Emmanuelli, J ^a   Quaglia, M ^c   Barin, F ^d   Arduin, P ^c   Laporte, A ^a   Desenclos, J C ^a  

^a National Institute for Public Health Surveillance   (France)

^b CNRS   (France)

^c INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

^d National Reference Center for HIV   (France)

^e INSTITUT DE VEILLE SANITAIRE   (France)

Author keywords

At risk behaviors; Drug users; Epidemiology; Harm reduction; Hepatitis C; Screening

Indexed keywords

ADULT; ARTICLE; ATTITUDE TO HEALTH; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABUSE; FEMALE; FRANCE; HARM REDUCTION; HEALTH CARE POLICY; HEPATITIS VIRUS; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SAMPLE SIZE; SCREENING; SELF REPORT; SEROLOGY; VIRUS TRANSMISSION;

ADULT; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HARM REDUCTION; HEALTH POLICY; HEPATITIS C; HIV SEROPOSITIVITY; HUMANS; MALE; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33747026928     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1080/10826080600847951     Document Type: Article

References (41)

1. Alter, M. J., Moyer, L. A. (1998). The importance of preventing hepatitis C virus infection among injection drug users in the United States. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 18:6-10.
2. Bailleau, F., Castel, R., Joubert, M. (1995). Harm reduction. Figleaf social policies. Aids Review
3. Becker, G. S., Murphy, K. (1988). A theory of rational addiction. Journal of Political Economy 96:675-700.
4. Brandt, A. M., Rozin, P. (1997). Morality and Health. New York: Routledge.
5. Bruandet, A., et al. (2005). Incidence and risk factors for seroconversion to hepatitis C in a cohort of intravenous drug users in north-eastern France. Weekly Epidemiological Bulletin 2:7-9.
6. Brousse, C., de la Rochère, B., Massé, E. (2000). Accommodation and distribution of hot meals: the case of the homeless. INSEE-First.
7. Brousse, C., de la Rochère, B., Massé, E. (2000). Accommodation and distribution of hot meals: the case of the homeless. INSEE-First
8. Centers for Disease Control and Prevention. (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 47:6-7.
9. Courtright, D. T. (2001). Forces of Habit. Cambridge, MA: Harvard University Press.
10. Couturier, E., et al. (1992). HIV infection at outcome of pregnancy in the Paris area, France. Lancet 340(8821):707-709.
11. Davis, G. L., Rodrigue, J. R. (2001). Treatment of chronic hepatitis C in active drug users. New England Journal of Medicine 345:215-217.
12. Des Jarlais, D. C., et al. (2003). Variability in the incidence of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection among young injecting drug users in New York City. American Journal of Epidemiology 157:467-471.
13. Emmanuelli, J., Desenclos, J. C. (2005). Monitoring harm reduction policy among intravenous drug users in France, 1996-2003. Addiction 100:1690-1700.
14. Emmanuelli, J., Lert, F., Valenciano, M. (1999). Study of injecting drug users using the main syringe exchange programs throughout France.
15. Emmanuelli, E., Jauffret-Roustide, M. (2003). A multicenter, multisite study of the frequency and determinants of practices at risk for HIV and HCV infection among drug users (Coquelicot study). Report by InVS on behalf of ANRS.
16. Evans, B. G., Abiteboul, D. (1999). A summary of occupationally acquired HIV infection described in published reports to December 1997. Eurosurveillance 4:29-32.
17. Fueller, M., Ompad, D. C., Galea, S., Wu, Y., Koblin, B., Vlahov, D. (2004). Hepatitis C incidence - a comparison between injection and noninjection drug users in New York City. Journal of Urban Health 81:20-24.
18. Galperim, B., et al. (2004). Intranasal cocaine use does not appear to be an independent risk factor for HCV infection. Addiction 99:973-977.
19. Goffman, E. (1952). On cooling the mark out: some aspects of adaptation to failure. Psychiatry 15:451-463.
20. Grando-Lemaire, V., et al. (2002). Management of hepatitis C virus infection among drug users followed in a specialized ambulatory center. Gastroentérol. Clin. Biol. 26:1091-1096.
21. Griffiths, P., Gossop, M., Powis, B., Strang, J. (1993). Reaching hidden populations of drug users by privileged access interviewers : methodological and practical issues. Addiction 88:1617-1626.
22. Jauffret, M. (2000). Harm reduction: challenges of collective mobilization. Mana. Review of Sociology and Antropology 161-188.
23. Jauffret-Roustide, M. (2004). Illicit Drugs: Sociological, Economic and Political Approaches. Paris: La Documentation française.
24. Judd, A., et al. (2004). Incidence of hepatite C virus and HIV among new injecting drug users in London: prospective cohort study. British Medical Journal 12/11
25. Kleinig, J. (2004). Ethical issues of substance use intervention. Substance Use and Misuse 40:3.
26. Koblin, B. A., Factor, S. H., Wu, Y., Vlahov, D. (2003). Hepatitis C virus infection among noninjecting drug users in New York City. Journal of Medical Virology 70:387-390.
27. Kuebler, D., Hausser, D., Gervasoni, J. P. (2000). The characteristics of "new users" of cocaine and heroin unknown to treatment agencies : results from the Swiss Hidden Population Study. Addiction 95(10):1561-1571.
28. MacCoun, R. J., Reuter, P. (2001). Drug War Heresies: Learning from Other Vices, Times and Places. London: Cambridge University Press.
29. MacCoy, C. B., Chitwood, D. D., Shapshak, P., Comerford, S. T. (1998). Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18(Suppl.1):S25-S29.
30. Magura, S. ed. (2000). Substance Use and Misuse 34:12-14.
31. Meyer, L., et al. (1996). Trends in HIV infection among sexually transmitted disease patients in Paris. AIDS 10:401-405.
32. Neale, J., Allen, D., Coombes, L. (2005). Qualitative research methods within the addictions. Addiction 100:1584-1593.
33. OFDT (French Observatory of Illicit Drugs and Addictions) (2002). Drugs and dependency, indicators and trends.
34. Porter, R., Teich, M., eds. (1995). Drugs and Narcotics in History. Cambridge: Cambridge University Press.
35. Power, R. (1995). A model for qualitative action research amongst illicit drug users. Addiction Research. 3:165-181.
36. Stark, K., Muller, R., Bienzle, U., Guggenmoos-Holzmann, I. (1996). Frontloading : a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS 10:311-317.
37. Six, C., Hamers, F., Brunet, J. (1999). Semester survey of HIV and HCV among residents of specialised care centers for addicts who are not homeless, Global Report on the last 10 semester surveys July 1993-June 1998, European center for AIDS epidemiologic surveillance.
38. Tortu, S., McMahon, J. M., Pouget, E. R., Hamid, R. Sharing of noninjection drug use implements as a risk factor for hepatitis C. Substance Use & Misuse 39:211-224.
39. Vidal-Trecan, G., et al. (2002). Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users. Annales de Medecine Interne. 153:219-225.
40. Vuchinich, R. E., Heather, N. (2003). Choice, Behavioral Economics and Addiction. New York: Pergamon.
41. Zwahlen, M., Vlahov, D. (2003). Commentary: modelling and understanding differences in human immunodeficiency and hepatitis C virus epidemiology in injection drug users. International Journal of Epidemiology 32:715-716.